Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Tribute Pharmaceuticals Canada Inc. | slx_ex991.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________
FORM
8-K
______________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 5, 2010
______________
Stellar
Pharmaceuticals Inc.
(Exact
name of registrant as specified in its charter)
______________
|
Ontario,
Canada
|
0-31198
|
Not
Applicable
|
|
(State
or Other Jurisdiction
|
(Commission
|
(I.R.S.
Employer
|
|
of
Incorporation)
|
File
Number)
|
Identification
No.)
|
544
Egerton Street, London, Ontario, Canada, N5W 3Z8
(Address
of Principal Executive Office) (Zip Code)
(519)
434-1540
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
7.01 Regulation FD Disclosure
See exhibit 99.1
Item
9.01 Financial
Statements and Exhibits.
(d)
Exhibits.
|
Exhibit
No.
|
Description
|
|
|
99.1
|
|
Stellar Pharmaceuticals signs licensing agreement for
distribution and sale of Uracyst® in
Portugal
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
|
STELLAR
PHARMACEUTICALS INC.
|
|
|
|
||
|
By:
|
/s/
Peter Riehl
|
|
|
Peter
Riehl
President
and Chief Executive Officer
|
||
Date: May
5, 2010